Trial Profile
A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 30 May 2016 Results (correction to previously published (citation #3168334) pooled subset analysis of ARCHER 1009 and A7471028 studies, n = 121) published in the Annals of Oncology.
- 13 Jan 2016 Results of subgroup analysis of pooled data from two studies (ARCHER 1009 and A7471028) published in the Annals of Oncology.
- 09 Sep 2015 Results of pooled analysis of A7471028 and ARCHER 1009 study presented at the 16th World Conference on Lung Cancer.